There is a significant need for development of alternative strategies for targeted kinase inhibition. As an alternative for selective kinase targeting, this study is focused on the development of chemically constrained peptides that target allosteric activation mechanisms. This proposal is the crucial first step in the development of a powerful new tool towards developing peptide-based allosteric inhibitors of kinases. The long-term goal of this work is to develop allosteric effectors that target kinase activation as it relates to cancer. The overall objective for this application is to develop novel, peptide-based compounds that disrupt protein-protein interactions (PPIs) involved in allosteric activation of EGFR. It is the central hypothesis that by targeting alternative conserved surfaces of EGFR that regulate PPIs rather than the ATP or EGF binding sites, EGFR can be effectively inhibited and this targeting strategy may retain activity in patients that are unresponsive to current EGFR-targeted therapies. The rationale underlying the proposed project is that the knowledge gained by developing allosteric EGFR inhibitors has the potential to translate into innovative, highly specific targeting strategies for successful inhibition of diverse kinases in cancer. This hypothesis will be tested by pursuing two specific aims: 1) Evaluate inhibitory properties of constrained EGFR dimerization arm peptides in different classes of resistance to EGFR-targeted therapies; and 2) Optimize inhibitory properties of constrained peptides mimicking the dimerization arm of EGFR. The expected outcomes of this work will be significant. First, this study will validate the concept that allosteric kinase activation mechanisms can be targeted for inhibition. Next, it will be determined whether these alternative targeting approaches can inhibit lung cancer cell lines that either differ in EGFR expression levels or are resistant to EGFR-targeted therapies by monitoring formation of ErbB homo- and heterodimers. ErbB inhibition will be extensively characterized in cell lines with various resistance mechanisms. In silico approaches will also be applied to optimize ligand binding and efficacy and will validate the compounds biochemically. Ultimately, the synthetic strategies developed in this study can also be applied to diverse protein-protein interaction surfaces. This work will contribute significantly to our understanding of designing compounds that target kinase allostery. The research proposed in this application is innovative because it represents a new and substantive departure from the status quo by proposing that PPIs play a significant role in kinase activation and therefore allosteric activation mechanisms can be targeted using alternative synthetic strategies including novel compounds included in this study that target and inhibit the PPI interface. This contribution is significant because it will undoubtedly reveal new, alternative approaches for inhibition of EGFR and other receptor tyrosine kinases.

Public Health Relevance

The proposed research is relevant to public health because targeting the allosteric activation mechanisms of EGFR is ultimately expected to provide new insights into novel strategies and targets for the treatment of cancer. The project is relevant to part of the NCI's mission that pertains to developing fundamental knowledge into the molecular mechanisms of cancer and developing advances to prevent cancer growth.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA188439-01A1
Application #
8949665
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kondapaka, Sudhir B
Project Start
2015-07-01
Project End
2017-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Georgia
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Autenrieth, Karolin; Bendzunas, N George; Bertinetti, Daniela et al. (2016) Defining A-Kinase Anchoring Protein (AKAP) Specificity for the Protein Kinase A Subunit RI (PKA-RI). Chembiochem 17:693-7
Bavencoffe, Alexis; Li, Yong; Wu, Zizhen et al. (2016) Persistent Electrical Activity in Primary Nociceptors after Spinal Cord Injury Is Maintained by Scaffolded Adenylyl Cyclase and Protein Kinase A and Is Associated with Altered Adenylyl Cyclase Regulation. J Neurosci 36:1660-8
Mohanty, Smita; Oruganty, Krishnadev; Kwon, Annie et al. (2016) Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization. PLoS Genet 12:e1005885
Teng, Yong; Bahassan, Abdulaziz; Dong, Dayong et al. (2016) Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion. Cancer Res 76:965-73
Teng, Yong; Qin, Haiyan; Bahassan, Abdulaziz et al. (2016) The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis. Cancer Res 76:5133-42
Götz, Frank; Roske, Yvette; Schulz, Maike Svenja et al. (2016) AKAP18:PKA-RIIα structure reveals crucial anchor points for recognition of regulatory subunits of PKA. Biochem J 473:1881-94
Kennedy, Eileen J; Scott, John D (2015) Selective disruption of the AKAP signaling complexes. Methods Mol Biol 1294:137-50
Kennedy, Eileen J; Kannan, Natarajan (2015) Dialing in EGFR Signaling. Chem Biol 22:687-8
Mohanty, Smita; Kennedy, Eileen J; Herberg, Friedrich W et al. (2015) Structural and evolutionary divergence of cyclic nucleotide binding domains in eukaryotic pathogens: Implications for drug design. Biochim Biophys Acta 1854:1575-85
Hanold, Laura E; Watkins, Christopher P; Ton, Norman T et al. (2015) Design of a selenylsulfide-bridged EGFR dimerization arm mimic. Bioorg Med Chem 23:2761-6